TITLE

HE4 combined with CA125: favorable screening tool for ovarian cancer

AUTHOR(S)
Ghasemi, Nasrin; Ghobadzadeh, Samira; Zahraei, Mahnaz; Mohammadpour, Hemn; Bahrami, Salahadin; ganje, Mohammad; Rajabi, Shokoh
PUB. DATE
January 2014
SOURCE
Medical Oncology;Jan2014, Vol. 31 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
93504305

 

Related Articles

  • PLCO: Where Are We Now? Coleman, Robert L. // OB/GYN Clinical Alert;May2009, Vol. 26 Issue 1, p6 

    In this article the author discusses the study which evaluates the impact of annual screening with trans-vaginal ultrasound and CA125 on ovarian cancer mortality. He argues that the great challenge of screening a low-risk population is the burden placed on the performance of the prescribed...

  • Ovarian cancer: Who needs screening? Piver, M. Steven; Recio, Fernando O. // Patient Care;12/15/1993, Vol. 27 Issue 20, p27 

    Focuses on the importance of screening high-risk patients with a combination of methods for ovarian cancer. Screening considerations; Benefits of screening; Pelvic examination; CA-125; Transvaginal sonography; Transvaginal color-flow Doppler imaging; Judicious screening. INSET: Treating...

  • HE4, CA-125, and cystic ovarian mass. Wiwanitkit, Viroj // Journal of Gynecologic Oncology;Jun2012, Vol. 23 Issue 2, p133 

    A letter to the editor is presented in response to the article about the use of HE4 and CA-125 as a biomarker tool for screening a pelvic mass or cystic ovarian mass.

  • Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. Jacobs, Ian J; Skates, Steven; Davies, Ann Prys; Woolas, Robert P; Jeyerajah, Arjun; Weidemann, Pru; Sibley, Karen; Oram, David H // BMJ: British Medical Journal (International Edition);11/30/96, Vol. 313 Issue 7069, p1355 

    Assesses the risk of ovarian and fallopian tube cancers associated with raised serum concentration of cancer (CA) 125 in asymptomatic women. Role of CA 125 in screening for ovarian cancer; Sensitivity of CA 125 in index cancer detection; Association between CA 125 concentration and risk of...

  • The Effectiveness of Ovarian Cancer Screening. Schapira, Marilyn M.; Matchar, David B.; Young, Mark J. // Annals of Internal Medicine;6/1/1993, Vol. 118 Issue 11, p838 

    Focuses on a study that estimated the effectiveness of ovarian cancer screening with CA 125 and transvaginal sonography. Natural history of ovarian cancer; Threshold values for the use of CA 125 and transvaginal sonography as combined tests; Estimates and threshold analysis for a cohort of 65...

  • Potential Markers for Detection and Monitoring of Ovarian Cancer. Rein, Brandon J. D.; Gupta, Sajal; Dada, Rima; Safi, Joelle; Michener, Chad; Agarwal, Ashok // Journal of Oncology;2011, p1 

    This paper reviews current screening techniques as well as novel biomarkers and their potential role in early detection of ovarian cancer. Ovarian cancer is one of the most common reproductive cancers and has the highest mortality rate amongst gynecologic cancers. Because most ovarian cancer...

  • Combining CA-125 and U/S best approach to ovarian Ca screening.  // Contemporary OB/GYN;Apr2009, Vol. 54 Issue 4, p22 

    The article discusses the findings of a research on combining CA-125 blood test and transvaginal ultrasound for ovarian screening tests published in "The Lancet Oncology." It notes that such combination has a high degree of sensitivity and specificity which is needed for all primary ovarian and...

  • Ascites with a raised CA 125. D'Souza, D. J.; Walker, E. J. // Journal of the Royal Society of Medicine;Aug1997, Vol. 90 Issue 8, p448 

    The article discusses a case study, where researchers investigated CA 125's, a soluble oncofetal antigen, effectiveness as a tumor marker for ovarian cancer. The case study relates to a 32-year-old Vietnamese woman with anemia, lymphopenia, and raised plasma viscosity. The woman's level of CA...

  • HE4, CA-125, and cystic ovarian mass: In reply. Sundfeldt, Karin // Journal of Gynecologic Oncology;Jun2012, Vol. 23 Issue 2, p133 

    A response by Karin Sundfeldt to a letter to the editor about his article on the use of HE4 and CA-125 as a biomarker tool for screening a pelvic mass or cystic ovarian mass is presented.

  • 卵巢癌早期诊断的血清肿瘤标记物研究进展. 岳娟; 刘菲; 李艳红 // Journal of International Obstetrics & Gynecology;Oct2015, Vol. 42 Issue 5, p560 

    Ovarian cancer is the most leading cause of death in gynecologic malignancies. Since lack of early detection strategies, the majority of the patients are diagnosed at advanced stage disease, of which the cure rate is only 20%-30%. It has been obsen^ed that the sundval rate of patients at early...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics